Related Experiment Video
Updated: Aug 8, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
Published on: December 23, 2010
Effects of novel leukotriene receptor antagonists in the isolated rat aorta
D N Serban1, I L Serban, M Nechifor
1Department of Physiology, University of Medicine and Pharmacy Grigore T. Popa Iasi, Universitatii 16, Iasi, Arcu 53-55, Bl. T12, En. A, Ap. 2, Iasi, RO 700134, Romania. dnserban@yahoo.com
Abstract:
We screened 14 novel antagonists of the LTB(4) and LTD(4) receptors (also inhibitors of LTB(4) synthesis) for their vasoactive properties in the isolated rat aorta. The compounds belong to three classes, e.g. quinoline (Q), phenetylamido (P), and resatophenone (R) derivatives. They are effectiveless in resting conditions and generally display a weak relaxing ability against contraction by either high K(+) or alpha(1) adrenoceptor activation, either in the presence or absence of a functional endothelium. There is little overlap with the generally lower concentration range where their anti-LT properties are already manifested. We could not find any correlation between any of the anti-LT properties and the vasorelaxant effects. Concerning the non-specific vasoactive properties, choice compounds of the examined groups could be further tested regarding the mechanisms of their relaxing effects. Given the many uncertainties concerning LT and vascular physiology, it may be worthy to proceed with this line of investigation.
More Related Videos
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

